Spots Global Cancer Trial Database for Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia
Official Title: Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients
Study ID: NCT01109264
Conditions
Study Description
Brief Summary: To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia
Detailed Description: Patients will be assessed for response after three cycles of treatment. Two additional cycles are recommended for CR, PR or SD patients, up to a maximum limit of six cycles in total. Patients will be followed up every three months until disease progression or death.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, , China
Contact Details
Name: Zhixiang Shen, Dr.
Affiliation: Ruijin Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
